<?xml version="1.0" encoding="UTF-8"?>
<p id="para230">During the Zika virus outbreak, companies had to pay large sums of money to acquire specimens for test development on the black market, often uncertain of the quality of specimen or its characterisation. Furthermore, once WHO declared that the Zika outbreak was no longer a Public Health Emergency of International Concern, funding for test development was quickly diverted elsewhere and the market disappeared overnight. For companies that have devoted substantial time and resources on test development, the opportunity costs are far too high. For the long term, sustainable mechanisms for accelerating diagnostic test development have to be established for diseases of epidemic potential.</p>
